LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

By LabMedica International staff writers
Posted on 23 Apr 2024
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the cancer often returns. Now, researchers have used spatial analysis of tissue samples to uncover patterns that could indicate whether patients with this form of ovarian cancer are likely to experience early recurrence following treatment, potentially guiding future therapeutic strategies.

Researchers at Cedars-Sinai (Los Angeles, CA, USA) conducted spatial protein analyses on ovarian cancer tissue samples to identify patterns correlated with early cancer relapse soon after treatment. The study involved 42 patients and examined both primary and recurrent tumors using imaging mass cytometry, which allows for the detailed spatial examination of protein presence within tissues. Their key findings highlighted the role of plasma cells in the tumor's immune response.

The study found that the location of plasma cells and their relationship with nearby cell types, such as cancer-associated fibroblasts, were crucial indicators of patient outcomes. These fibroblasts, which hamper the effectiveness of immune cells, were frequently found in areas with plasma cells, suggesting that they may affect the plasma cells' ability to communicate with other immune cells, thus contributing to poorer outcomes in patients.

“Using spatial protein analysis, we looked not only at the types of cells within and around a tumor, but also at their relative positions and how they interact,” said Alex Xu, PhD, a research scientist at Cedars-Sinai Cancer. “Our findings suggest that plasma cells are a clinically important factor determining a patient’s time to relapse.”

Related Links:
Cedars-Sinai

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more